Leukemia Research
Volume 33, Issue 11 , Pages 1481-1484 , November 2009

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis

  • Arturo Vega-Ruiz

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States
    • ,
  • Jorge E. Cortes

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States
    • ,
  • Matjaz Sever

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States
    • ,
  • Taghi Manshouri

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States
    • ,
  • Alfonso Quintás-Cardama

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States
    • ,
  • Raja Luthra

      Affiliations

    • Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States
    • ,
  • Hagop M. Kantarjian

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States
    • ,
  • Srdan Verstovsek

      Affiliations

    • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States
    • Corresponding Author InformationCorresponding author at: UT MD Anderson Cancer Center, Department of Leukemia, Unit 428, 1515 Holcombe Boulevard, Houston, TX 77030, United States. Tel.: +1 713 745 3429; fax: +1 713 794 4297.

Received 25 November 2008 ,Revised 18 December 2008 ,Accepted 23 December 2008.

References 

  1. Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology. 2007;74:121–132
  2. Patnaik MM, Tefferi A, Pardanani A. Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders. Curr Cancer Drug Target. 2007;7:492–503
  3. Furitsu T, TsujimuraT , Tono T, et al. Identifications of mutations in the coding sequence of the proto-oncogen c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest. 1993;92:1736–1744
  4. Quintas-Cardama A, Aribi A, Cortes J, et al. Novel approaches in the treatment of systemic mastocytosis. Cancer. 2006;107:1429–1439
  5. Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99:1741–1744
  6. Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, et al. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006;107:345–351
  7. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25(7):603–625
  8. Piccaluga PP, Rondoni M, Paolini S, et al. Imatinib mesylate in the treatment of hematologic malignancies. Expert Opin Biol Ther. 2007;7:1597–1611
  9. Pardanani A, Elliot M, Reeder T, et al. Imatinib for systemic mast cell disease. Lancet. 2003;362:535–537
  10. Akin C, Fumo G, Yavuz AS, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 2004;103:3222–3225
  11. Frost MJ, Ferrao PT, Hughes TP, et al. Juxtamembrane mutant V560Gkit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase mutant D816Vkit is resistant. Mol Cancer Ther. 2002;1:1115–1124

PII: S0145-2126(08)00567-5

doi: 10.1016/j.leukres.2008.12.020

Leukemia Research
Volume 33, Issue 11 , Pages 1481-1484 , November 2009

Article Tools

* Image Usage & Resolution